For the record, I never thought Advaxis was a scam, and still don't. I do believe they made some fundamental mistakes that put them in the position they are now. I lay most of this on DOC. While he's the person who got institutions interested and got the price to $30, he's also the one who bit off more than could be chewed. I believe that HE believed that the tech was so good and compelling nothing could stop the rise. But he was dead wrong. He hired boat loads of folks for research and put the company on a path for 2 new platforms - NEO and HOT. But he did this without income, relying on the money he raised and an unreasonable (in hindsight) expectation of imminent success. But he could and should have foreseen the money running out. (So should we all have). What I believe should have been done instead was to use that money to have more, perhaps many more, clinical trial sites for AIM2CERV, thereby getting more patients enrolled sooner and hopefully getting an approved product on the shelf generating income. THEN it would be time for NEO and HOT to get developed. Now Advaxis is a hot mess and is resetting the clock, leaving long term investors holding the bag. Amgen leaving says NOTHING about the future possible success of AIM2CERV, it's a different platform, and it's still a Phase III trial. Advaxis for all it's faults has seen the error and is trying to correct it by asking the FDA to approve a redesign to the trial for earlier reading. They also know they will run out of money soon and must, MUST, dilute and r/s to stay listed.
I sold a few months ago, and like I've said before, I believe they'll be an opportunity to re-enter after the above mentioned nastiness. If they offer warrants I'll probably buy those since they'll likely expire well after AIM2CERV is scheduled for completion.
Good luck to all, whatever you decide.
Have a happy new year. Hug everyone you love, and some you don't.
